Alumis Inc.

Alumis Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing medicines for autoimmune disorders. Its lead product candidate is envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor being studied for plaque psoriasis and systemic lupus erythematosus. The company also has A-005, a central nervous system-penetrant allosteric TYK2 inhibitor in Phase 1 for neuroinflammatory and neurodegenerative diseases. Additionally, Alumis is developing lonigutamab, a monoclonal antibody targeting IGF-1R for thyroid eye diseases, and an interferon regulatory factor 5 (IRF5) program to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. before rebranding in January 2022.

Alumis Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ALMS. Its shares trade in United States Dollars (USD). As a company headquartered in South San Francisco, California, it operates within the U.S. capital markets, and its financial reporting is conducted in USD. Investors can trade ALMS shares during regular Nasdaq trading hours.

Alumis Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. Biotechnology companies like Alumis focus on using biological processes and living organisms to develop drugs and therapies. In Alumis's case, it is a clinical-stage biopharmaceutical company that develops small molecule inhibitors and monoclonal antibodies for autoimmune and inflammatory diseases. This industry is characterized by high research and development costs, long product development cycles, and significant regulatory oversight.

Alumis Inc. is headquartered in South San Francisco, California, United States. The company primarily serves the U.S. market, as indicated by its country and region being the United States and 'us'. Its focus is on developing therapies for autoimmune disorders, which affect a significant patient population in the U.S. and globally. While the company is U.S.-based, its clinical trials and potential future commercial activities may extend to other regions, but the available data only confirms its U.S. operations and headquarters.

Alumis Inc. has a pipeline focused on autoimmune and inflammatory diseases. Its lead candidate is envudeucitinib, a TYK2 inhibitor for plaque psoriasis and systemic lupus erythematosus. Another candidate is A-005, a CNS-penetrant allosteric TYK2 inhibitor in Phase 1 for neuroinflammatory and neurodegenerative diseases. The company also develops lonigutamab, a monoclonal antibody targeting IGF-1R for thyroid eye diseases, and an IRF5 program aimed at immune dysfunction. These candidates represent different modalities, including small molecules and antibodies, targeting various immune-mediated conditions.